These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 27844413)

  • 21. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
    Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
    Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic Performance of
    Qiu ZL; Wei WJ; Shen CT; Song HJ; Zhang XY; Sun ZK; Luo QY
    Sci Rep; 2017 Jun; 7(1):2849. PubMed ID: 28588229
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic significance of thyroglobulin antibody epitopes in differentiated thyroid cancer.
    Lupoli GA; Okosieme OE; Evans C; Clark PM; Pickett AJ; Premawardhana LD; Lupoli G; Lazarus JH
    J Clin Endocrinol Metab; 2015 Jan; 100(1):100-8. PubMed ID: 25322272
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progression free survival related to
    Zhu X; Wu S; Yuan X; Wang H; Ma C
    Hell J Nucl Med; 2019; 22(2):123-130. PubMed ID: 31273354
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changing Trend of Thyroglobulin Antibodies in Patients With Differentiated Thyroid Cancer Treated With Total Thyroidectomy Without
    Matrone A; Latrofa F; Torregrossa L; Piaggi P; Gambale C; Faranda A; Ricci D; Agate L; Molinaro E; Basolo F; Vitti P; Elisei R
    Thyroid; 2018 Jul; 28(7):871-879. PubMed ID: 29860933
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Postradioiodine treatment whole-body scan in the era of 18-fluorodeoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels.
    Leboulleux S; El Bez I; Borget I; Elleuch M; Déandreis D; Al Ghuzlan A; Chougnet C; Bidault F; Mirghani H; Lumbroso J; Hartl D; Baudin E; Schlumberger M
    Thyroid; 2012 Aug; 22(8):832-8. PubMed ID: 22853728
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic value of thyroglobulin measurement with fine-needle aspiration biopsy for lymph node metastases in patients with a history of differentiated thyroid cancer.
    Zhang HS; Wang RJ; Fu QF; Gao S; Sun BT; Sun H; Ma QJ
    Asian Pac J Cancer Prev; 2014; 15(24):10905-9. PubMed ID: 25605199
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical utility of 18F-FDG PET/CT concurrent with 131I therapy in intermediate-to-high-risk patients with differentiated thyroid cancer: dual-center experience with 286 patients.
    Lee JW; Lee SM; Lee DH; Kim YJ
    J Nucl Med; 2013 Aug; 54(8):1230-6. PubMed ID: 23813775
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan.
    Trybek T; Kowalska A; Lesiak J; Młynarczyk J
    Nucl Med Rev Cent East Eur; 2014; 17(2):87-93. PubMed ID: 25088108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relationship between positive thyroglobulin doubling time and 18F-FDG PET/CT-positive, 131I-negative lesions.
    Kelders A; Kennes LN; Krohn T; Behrendt FF; Mottaghy FM; Verburg FA
    Nucl Med Commun; 2014 Feb; 35(2):176-81. PubMed ID: 24201550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of FDG-PET/CT in differentiated thyroid cancer patients with negative iodine-131 whole-body scan and elevated anti-Tg level.
    Asa S; Aksoy SY; Vatankulu B; Aliyev A; Uslu L; Ozhan M; Sager S; Halac M; Sonmezoglu K
    Ann Nucl Med; 2014 Dec; 28(10):970-9. PubMed ID: 25120245
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Usefulness of the combined antithyroglobulin antibodies and thyroglobulin assay in the follow-up of patients with differentiated thyroid cancer.
    Rubello D; Girelli ME; Casara D; Piccolo M; Perin A; Busnardo B
    J Endocrinol Invest; 1990 Oct; 13(9):737-42. PubMed ID: 2292657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
    Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY
    J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
    Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The usefulness of fluorine-18 fluorodeoxyglucose PET in the detection of recurrence in patients with differentiated thyroid cancer with elevated thyroglobulin and negative radioiodine whole-body scan.
    Stangierski A; Kaznowski J; Wolinski K; Jodlowska E; Michaliszyn P; Kubiak K; Czepczynski R; Ruchala M
    Nucl Med Commun; 2016 Sep; 37(9):935-8. PubMed ID: 27383190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can (18)F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan?
    Bannas P; Derlin T; Groth M; Apostolova I; Adam G; Mester J; Klutmann S
    Ann Nucl Med; 2012 Jan; 26(1):77-85. PubMed ID: 22006540
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.
    Wang W; Macapinlac H; Larson SM; Yeh SD; Akhurst T; Finn RD; Rosai J; Robbins RJ
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2291-302. PubMed ID: 10404792
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 68Ga-DOTATOC PET/CT in Patients with Iodine- and 18F-FDG-Negative Differentiated Thyroid Carcinoma and Elevated Serum Thyroglobulin.
    Binse I; Poeppel TD; Ruhlmann M; Ezziddin S; Görges R; Sabet A; Beiderwellen K; Bockisch A; Rosenbaum-Krumme SJ
    J Nucl Med; 2016 Oct; 57(10):1512-1517. PubMed ID: 27033897
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Thyroglobulin antibodies in differentiated thyroid cancer.
    Hjiyiannakis P; Mundy J; Harmer C
    Clin Oncol (R Coll Radiol); 1999; 11(4):240-4. PubMed ID: 10473720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Could [18]F-fluorodeoxyglucose PET/CT change the therapeutic management of stage IV thyroid cancer with positive (131)I whole body scan?
    Piccardo A; Foppiani L; Morbelli S; Bianchi P; Barbera F; Biscaldi E; Altrinetti V; Villavecchia G; Cabria M
    Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):57-65. PubMed ID: 21285923
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.